Zydus Life Science , a leading Indian pharmaceutical company, has successfully completed the acquisition of a controlling stake in Amplitude Surgical SA, a French orthopedic surgical technology firm. The deal, which was first announced on March 11, 2025, marks a significant expansion for Zydus into the global orthopedic market.

Key Highlights of the Acquisition

• Zydus acquired an 85.6% stake in Amplitude Surgical for €256.8 million (approximately ₹2,310.00 crore).
• The acquisition was completed on July 29, 2025, through Zydus MedTech (France) SAS, a wholly-owned subsidiary of Zydus MedTech Private Limited.
• The purchase price was set at €6.25 per share.

Upcoming Mandatory Tender Offer

Following the completion of the block acquisition, Zydus is set to initiate further steps to consolidate its ownership:

• A simplified mandatory tender offer will be filed on July 30, 2025, for the remaining outstanding shares at the same price of €6.25 per share.
• Seven shareholders, representing 4.7% of Amplitude Surgical's share capital, have already committed to participate in the tender offer.
• Upon completion of the offer, Zydus is expected to hold more than 90% of Amplitude Surgical's capital and voting rights.
• Zydus intends to implement a squeeze-out of remaining minority shareholders after the tender offer.

Timeline and Regulatory Approval

• The tender offer is anticipated to open in September 2025, subject to clearance from the French Financial Market Authority (Autorité des marchés financiers, AMF).
• No additional regulatory approvals are required for the tender offer.

Management and Board Developments

• Olivier Jallabert will continue in his role as CEO of Amplitude Surgical.
• Amplitude Surgical's Board of Directors unanimously welcomed the offer on July 28, 2025.
• An independent expert, Finexsi, provided a fairness opinion on the offer.

About Amplitude Surgical

Amplitude Surgical, founded in 1997 in Valence, France, is a prominent player in the surgical technologies market for lower limb orthopedics. The company:

• Develops and markets high-end orthopedic surgery products, focusing on hip and knee pathologies.
• Collaborates closely with surgeons to create innovative solutions.
• Has an international presence through subsidiaries and a network of agents and distributors in over 30 countries.
• Employed 429 people and generated revenue of nearly €111.00 million as of June 30, 2025.

Strategic Implications for Zydus Lifesciences

This acquisition aligns with Zydus Lifesciences' mission to empower people with healthier and more fulfilled lives. By integrating Amplitude Surgical's expertise in orthopedic surgical technologies, Zydus is poised to:

• Expand its global footprint in the healthcare sector.
• Enhance its portfolio in the high-value orthopedic market.
• Leverage synergies between its existing pharmaceutical business and Amplitude's medical device capabilities.

The successful completion of this acquisition marks a significant milestone for Zydus Lifesciences, positioning the company for growth in the global orthopedic surgical market and reinforcing its commitment to innovative healthcare solutions.

Zydus Life Science has achieved a significant milestone in its pharmaceutical portfolio expansion. The company announced that it has received final approval from the United States Food and Drug Administration (USFDA) for Celecoxib Capsules in multiple strengths.

FDA Approval Details

The approval covers Celecoxib Capsules in four strengths:

• 50 mg
• 100 mg
• 200 mg
• 400 mg

This generic version is equivalent to the brand-name drug Celebrex® Capsules, which is widely used for pain management.

About Celecoxib

Celecoxib is classified as a nonsteroidal anti-inflammatory drug (NSAID). It functions by reducing hormones that cause inflammation and pain in the body. The drug is prescribed for various conditions, including:

• Arthritis
• Ankylosing spondylitis
• Menstrual pain
• Juvenile rheumatoid arthritis in children 2 years and older

Market Potential

The approval positions Zydus Lifesciences to tap into a substantial market. According to IQVIA data, Celecoxib capsules generated annual sales of $122.60 million in the United States for the 12 months ending May 2025.

Manufacturing and Production

Zydus will manufacture the newly approved Celecoxib capsules at its state-of-the-art facility:

• Location: Zydus Lifesciences Ltd (SEZ), Ahmedabad

Zydus's Growing Portfolio

This latest approval further strengthens Zydus's position in the U.S. pharmaceutical market:

• Total FDA Approvals: 428
• ANDA Filings: 492 (as of March 31, 2025)

The company has been consistently expanding its portfolio since it began filing ANDAs in the 2003-04 fiscal year.

Company Statement

Dhaval N. Soni, Company Secretary and Compliance Officer of Zydus Lifesciences Limited, confirmed the approval in a press release to the stock exchanges, emphasizing the company's commitment to expanding its pharmaceutical offerings and addressing patient needs in pain management.

This FDA approval marks another step forward for Zydus Lifesciences in its mission to provide accessible and effective healthcare solutions to patients in the United States and globally.